Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial

Summary

The main objective of the EvER-ILD2 study is to evaluate the efficacy on lung function at 6 months of one course rituximab (2 infusions) comparatively to one course of placebo (2 infusions) in a broad range of progressive ILD patients with inflammatory component.

Timeline

Start

2023-01-16

Primary completion

2026-07-16

Completion

2026-07-16

Publications

• Ferreira M, Bejan-Angoulvant T, Marchand-Adam S, Mousset E, Mureau E, Jouneau S, Nunes H, Montani D, Chenivesse C, Cadranel J, Bonniaud P, Crestani B, Cottin V, Caille A; OrphaLung.. Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial. Respir Med Res. 2025 May;87:101144. doi: 10.1016/j.resmer.2024.101144. Epub 2024 Nov 28.
• Barnes H, Corte TJ, Keir G, Khor YH, Limaye S, Wrobel JP, Veitch E, Harrington J, Dowman L, Beckert L, Milne D, De Losa R, Cooper WA, Bell PT, Balakrishnan P, Troy LK. Diagnosis and management of hypersensitivity pneumonitis in adults: A position statement from the Thoracic Society of Australia and New Zealand. Respirology. 2024 Dec;29(12):1023-1046. doi: 10.1111/resp.14847. Epub 2024 Oct 28.

Drugs

Indications